- Home
- APLM vs APTO Comparison
APLM vs APTO Comparison
Compare APLM & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- APTO
- Stock Information
- Founded
- APLM 2016
- APTO 1986
- Country
- APLM United States
- APTO Canada
- Employees
- APLM N/A
- APTO N/A
- Industry
- APLM Blank Checks
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLM Finance
- APTO Health Care
- Exchange
- APLM Nasdaq
- APTO Nasdaq
- Market Cap
- APLM 12.3M
- APTO 13.2M
- IPO Year
- APLM N/A
- APTO N/A
- Fundamental
- Price
- APLM $7.02
- APTO $0.16
- Analyst Decision
- APLM Strong Buy
- APTO Strong Buy
- Analyst Count
- APLM 2
- APTO 3
- Target Price
- APLM $425.00
- APTO $4.33
- AVG Volume (30 Days)
- APLM 7.4K
- APTO 17.4M
- Earning Date
- APLM 03-04-2025
- APTO 03-25-2025
- Dividend Yield
- APLM N/A
- APTO N/A
- EPS Growth
- APLM N/A
- APTO N/A
- EPS
- APLM N/A
- APTO N/A
- Revenue
- APLM $2,101,000.00
- APTO N/A
- Revenue This Year
- APLM N/A
- APTO N/A
- Revenue Next Year
- APLM N/A
- APTO N/A
- P/E Ratio
- APLM N/A
- APTO N/A
- Revenue Growth
- APLM 70.54
- APTO N/A
- 52 Week Low
- APLM $6.38
- APTO $0.13
- 52 Week High
- APLM $80.50
- APTO $1.94
- Technical
- Relative Strength Index (RSI)
- APLM 37.88
- APTO 42.85
- Support Level
- APLM $6.70
- APTO $0.13
- Resistance Level
- APLM $7.60
- APTO $0.26
- Average True Range (ATR)
- APLM 0.70
- APTO 0.02
- MACD
- APLM -0.03
- APTO -0.00
- Stochastic Oscillator
- APLM 22.30
- APTO 24.69
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.